A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients
Efficacy and Safety of Alefacept in Combination With Tacrolimus, Mycophenolate Mofetil and Steroids in de Novo Kidney Transplantation - a Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
-
Manchester、イギリス、M13 9WL
-
-
-
-
-
Bologna、イタリア、40138
-
Padova、イタリア、35128
-
Rome、イタリア、00168
-
Siena、イタリア、53100
-
-
-
-
-
Maastricht、オランダ、6229
-
-
-
-
-
Vienna、オーストリア、1090
-
-
-
-
-
Goteborg、スウェーデン、41345
-
Uppsala、スウェーデン、75185
-
-
-
-
-
Barcelona、スペイン、8036
-
Llobregat、スペイン、8907
-
Madrid、スペイン、28041
-
Malaga、スペイン、29010
-
Santander、スペイン、39008
-
-
-
-
-
Praha、チェコ共和国、140 21
-
-
-
-
-
Bochum、ドイツ、44892
-
Regensburg、ドイツ、93053
-
-
-
-
-
Budapest、ハンガリー、1082
-
-
-
-
-
Creteil、フランス、94010
-
Le Kremlin Bicetre Cedex、フランス、94275
-
Montpellier、フランス、34295
-
Nantes Cedex 1、フランス、44093
-
Nice Cedex 1、フランス、6002
-
Paris、フランス、75475
-
Toulouse Cedex、フランス、31054
-
-
-
-
-
Bruxelles、ベルギー、1070
-
Bruxelles、ベルギー、1200
-
Gent、ベルギー、9000
-
Leuven、ベルギー、3000
-
Liege、ベルギー、4000
-
-
-
-
-
Bydgoszcz、ポーランド、85-094
-
Poznan、ポーランド、60-479
-
Szczecin、ポーランド、70-111
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Subject with end stage kidney disease who is a suitable candidate for primary kidney transplantation or retransplantation
- Male or female subject at least 18 years of age and younger than 65 years
- Subject receiving a kidney transplant from a non-human leucocyte antigen (HLA) identical living donor or deceased HLA identical/non-HLA identical donor between 5 and 59 years of age with compatible ABO blood type (Blood group system A, B, AB and 0)
Exclusion Criteria:
- Subject has a panel reactivity antibody grade > 20% in the previous 6 months and/or had had a previous graft survival shorter than 1 year due to immunological reasons
- Subject received a kidney transplant from a non-heart beating donor
- Subject has received a kidney transplant from a 50 - 59 year old donor with two of the following three factors: history of hypertension, cerebrovascular accident as cause of death, final pre-procurement serum creatinine > 1.5 mg/dL (united network for organ sharing [UNOS] expanded criteria donor)
- Cold ischemia time of the donor kidney is ≥ 30 hours
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
プラセボコンパレーター:Placebo
Participants received placebo administered intra-operatively as an intravenous (IV) bolus on Day 0, another IV bolus on Day 3 and weekly subcutaneous injections thereafter for 12 weeks.
Participants also received tacrolimus, mycophenolate mofetil (MMF) and steroid treatment.
|
IV and subcutaneous injection
The initial daily dose was 0.2 mg/kg orally given in 2 doses commencing 24 hours after completion of surgery.
Mycophenolic mofetil was administered as 750 mg twice per day orally
Methylprednisolone or equivalent: Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus Prednisone or equivalent: Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally |
実験的:Alefacept
Participants received 7.5 mg alefacept administered intra-operatively as an IV bolus on Day 0, another 7.5 mg IV bolus on Day 3, and weekly subcutaneous injections of 15 mg alefacept thereafter for 12 weeks.
Participants also received tacrolimus, MMF and steroid treatment.
|
The initial daily dose was 0.2 mg/kg orally given in 2 doses commencing 24 hours after completion of surgery.
Mycophenolic mofetil was administered as 750 mg twice per day orally
Methylprednisolone or equivalent: Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus Prednisone or equivalent: Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally
IV and subcutaneous injection
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Percentage of Participants With Biopsy-confirmed Acute T-cell Mediated Rejection at Month 6 Assessed by Local Review
時間枠:6 months
|
Biopsies were graded by the clinical site pathologist.according to the Banff 97/05 updated histological classification:
A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade ≥ 1. The Kaplan-Meier estimate of biopsy-confirmed acute T-cell mediated rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit. |
6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Percentage of Participants With Biopsy Confirmed Antibody-Mediated Acute Rejection at Month 6
時間枠:6 months
|
Biopsies were graded by the clinical site pathologist.according to the Banff 97/05 updated histological classification: Acute antibody-mediated rejection - documented anti-donor antibody ('suspicious for' if antibody not demonstrated):
A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade ≥ 1. The Kaplan-Meier estimate of biopsy-confirmed antibody-mediated acute rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit. |
6 months
|
Percentage of Participants With Biopsy Confirmed Acute Rejection (T-Cell Mediated or Antibody Mediated) at Month 6
時間枠:6 months
|
Biopsies were graded by the clinical site pathologist.according to the Banff 97/05 updated histological classification. A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade ≥ 1. The Kaplan-Meier estimate of biopsy-confirmed acute T-cell mediated or antibody-mediated rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit. |
6 months
|
Percentage of Participants With Biopsy Confirmed Acute Mixed T-Cell Mediated and Antibody-Mediated Rejection at Month 6
時間枠:6 months
|
Biopsies were graded by the clinical site pathologist.according to the Banff 97/05 updated histological classification. A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade ≥ 1. The Kaplan-Meier estimate of biopsy-confirmed acute mixed T-cell mediated and antibody-mediated rejections within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit. |
6 months
|
Percentage of Participants With Acute Rejection Diagnosed by Signs and Symptoms at Month 6
時間枠:6 months
|
Acute rejection diagnosed by signs and symptoms, including biopsy-confirmed or suspected (not confirmed by biopsy - i.e. no biopsy was performed or biopsy did not confirm an acute T-cell mediated rejection).
The Kaplan-Meier estimate of acute rejection diagnosed by signs and symptoms within the first 6 months following transplantation is reported.
Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.
|
6 months
|
Percentage of Participants With Clinically Treated Acute Rejection at Month 6
時間枠:6 months
|
Patients who received immunosuppressive medications for the treatment of suspected or biopsy-confirmed acute rejections were considered to have a clinically-treated acute rejection.
The Kaplan-Meier estimate of clinically treated acute rejection within the first 6 months following transplantation is reported.
Participants lost to follow-up or with missing outcomes were censored at their last follow-up visit.
|
6 months
|
Percentage of Participants With Steroid-resistant Acute Rejection at Month 6
時間枠:6 months
|
A steroid-resistant acute rejection is defined as a rejection episode which did not resolve following treatment with corticosteroids. In the case that a rejection episode was not treated with corticosteroids first but only with antibodies, it was included in this category. The Kaplan-Meier estimate of steroid-resistant acute rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit. |
6 months
|
Percentage of Participants With Biopsy-Confirmed Acute T-cell Mediated Rejection as Assessed by Central Review at Month 6
時間枠:6 months
|
Biopsies were graded by the central reviewer according to the Banff 97/05 updated histological classification. A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade ≥ 1. The Kaplan-Meier estimate of biopsy-confirmed acute T-cell mediated rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit. |
6 months
|
Patient Survival
時間枠:6 months
|
Patient survival is any participant known to be alive at Month 6.
The Kaplan-Meier estimate of patient survival within the first 6 months following transplantation is reported.
Participants lost to follow-up were censored at the time of last assessment.
|
6 months
|
Graft Survival
時間枠:6 months
|
Graft survival was defined as any participant who was known to have a functioning graft (i.e., not graft loss) at 6 months. Graft loss is defined as re-transplantation, nephrectomy, death or as dialysis ongoing at end of study or at discontinuation of the participant unless superseded by follow-up information. The Kaplan-Meier estimate of graft survival within the first 6 months following transplantation is reported. Participants lost to follow-up were censored at the time of last assessment. |
6 months
|
Maximum Histological Grade of All Biopsies After Local Review
時間枠:6 months
|
The grade of acute rejection was classified according to Banff 97/05 updated version. If a patient had more than 1 rejection episode, the episode with the most severe grade was used. Acute T-cell mediated rejection:
Acute antibody-mediated rejection:
|
6 months
|
Percentage of Participants With Anti-Lymphocyte Antibody Therapy for Treatment of Rejection at Month 6
時間枠:6 months
|
The Kaplan-Meier estimate of anti-lymphocyte antibody therapy for acute rejection (clinically-treated or biopsy-confirmed) within the first 6 months following transplantation is reported.
Participants lost to follow-up or with missing outcomes were censored at their last follow-up visit.
|
6 months
|
Change From Month 1 in Serum Creatinine
時間枠:Month 1, 3, and 6
|
Month 1, 3, and 6
|
|
Change From Month 1 in Glomerular Filtration Rate (GFR)
時間枠:Month 1, 3, and 6
|
The GFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula.
|
Month 1, 3, and 6
|
Change From Month 1 in Creatinine Clearance
時間枠:Month 1, 3, and 6
|
The creatinine clearance was calculated according to the Cockcroft-Gault formula.
|
Month 1, 3, and 6
|
GFR Measured by Iothalamate Clearance at Month 6
時間枠:Month 6
|
GFR measured using the iothalamate clearance method and determined by a central laboratory.
|
Month 6
|
Percentage of Participants With Efficacy Failure at Month 6
時間枠:6 months
|
Efficacy failure is defined as death, graft loss, biopsy-confirmed acute T-cell mediated rejection assessed by local reading or lost to follow-up. The Kaplan-Meier estimate of efficacy failure within the first 6 months following transplantation is reported. |
6 months
|
Percentage of Participants With Delayed Graft Function
時間枠:1 week
|
Delayed graft function was defined as the requirement for dialysis within the first week post-transplant.
|
1 week
|
Percentage of Participants With Treatment Failure at Month 6
時間枠:6 months
|
Treatment failure is defined as efficacy failure (death, graft loss, biopsy-confirmed acute T-cell mediated rejection assessed by local reading, lost to follow-up) or early discontinuation of alefacept/placebo at any time (during the 12-week administration period) for any reason.
The Kaplan-Meier estimate of treatment failure within the first 6 months following transplantation is reported.
Participants lost to follow-up or with missing outcomes were censored at their last follow-up visit.
|
6 months
|
Number of Participants With Adverse Events
時間枠:6 Months
|
Causally related was defined as adverse events (AEs) assessed by the Investigator as possibly or probably related to study drug or records where the relationship was missing. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose:
All rejections and any BK virus, Epstein Barr virus and/or cytomegalovirus infection had to be reported as an SAE |
6 Months
|
協力者と研究者
スポンサー
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
デノボ腎移植の臨床試験
-
University Children's Hospital BaselSwiss National Science Foundation; Fondation Botnar完了
-
Biotronik AG完了
-
Novartis Pharmaceuticals完了
-
Novartis Pharmaceuticals完了EC-MPS による治療に関心があり、コア研究の 12 か月の治療期間を無事に完了した患者 (de novo Heart Recipients)
-
Boston Scientific Corporation完了
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ Transplantation; Cooperative Clinical Trials in Pediatric Transplantation...完了腎臓移植 | 腎移植レシピエント | 移植機能/生存 | de Novo HLA 抗体の開発アメリカ
placeboの臨床試験
-
Palacky University完了
-
Universidade Federal do ParaConselho Nacional de Desenvolvimento Científico e Tecnológico完了
-
Advice Pharma Group srl積極的、募集していない肥満 | 栄養障害 | 体重 | 減量 | 食生活 | 太りすぎと肥満 | 健康行動 | ダイエット、健康 | ダイエット習慣 | ライフスタイル | 栄養、健康 | 行動障害イタリア
-
University Hospital, Strasbourg, France積極的、募集していない